    
The links after "Participants" show which Southwest Oncology Group institutions are eligible to participate in this study.
The orange "Where is This Study Open?" tab at the bottom of the page shows the institutions whose Institutional Review Boards (IRBs) have approved the protocol so that it can be opened at that institution. Clicking on the Institution Name will show the points of contact for information about this study at that institution.
|
|
CTSU/E1105
- Phase III Intergroup(Closed)
|
| A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer |
|
Treatment: Bevacizumab, Trastuzumab
Disease Committee: Breast Cancer
|
|
Study Coordinator(s): Mohammad Jahanzeb, M.D. Participants: CTSU Eligibility Criteria: The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.
|
Activation Date: 12/1/2007
Closure Date: 10/28/2009
|
| IRB approval information is not available for CTSU protocols |
